The surveys and the trials tell opposite stories. Diary-keepers who chose to microdose report better mood, focus, and calm 1 — but that self-selecting group is a placebo machine, not a test of the drug. Blind them and it vanishes: when microdosers mixed real capsules with placebos, mood, depression, and anxiety improved equally in both arms 2. Controlled lab trials found no effect on memory or cognition, and creativity that ran slower 345. The 2024 review of every blinded study agreed 6.
One signal survives. People with existing depression felt more from a low LSD dose than from placebo, and scored lower 48 hours later 7 — one subgroup, one study, but the only blinded hint of something real. If you have mild-to-moderate depression, this is genuinely unsettled; if you don't, it isn't.
If you try it anyway, run it as a defined test with an end date, comparing dose days against off days.
Calibration is the trap: mushrooms vary tenfold in potency between batches, so a volumetric LSD tincture is the only reliably measured form.
How the six weeks tend to go. Day one brings a faint warmth and a mood most call "a good day, deliberately" — exactly what placebo days produce 2. By week three the dose-day effect dims as tolerance builds 3. At the end, most feel a little better off but can't say how much was the drug versus the attention.
The problems it claims to fix have better-evidenced, legal answers: an SSRI plus CBT for depression (or licensed full-dose psilocybin therapy), CBT and exercise for anxiety, an ADHD diagnosis and a prescriber for attention. For creative block, blinded microdose data is null or negative 3.
The legal reality most guides skip: in 2026, possessing LSD or psilocybin is a federal felony almost everywhere, at any dose 11. Colorado is the one clean personal-use safe harbour, having decriminalized possession and home cultivation for adults 21+ 12. City "deprioritization" votes only lower police priority.
The fine print — when to skip it, and what people get wrong
Skip it with valvular or structural heart disease: psychedelics bind the receptor whose chronic activation caused fenfluramine's valve damage 910. Also skip with an SSRI, MAOI, lithium, or a psychosis or bipolar I history.
"Sub-perceptual means safe" is wrong: you can't feel the receptor activity, which is the point of the fenfluramine comparison. "The community knows it works" describes a self-selected placebo machine, never a control group.
- 1Anderson T, Petranker R, Christopher A, Rosenbaum D, Weissman C, Dinh-Williams LA, Hui K, Hapke E (2019). Psychedelic microdosing benefits and challenges: an empirical codebook. Harm Reduction Journal. link
- 2Szigeti B, Kartner L, Blemings A, Rosas F, Feilding A, Nutt DJ, Carhart-Harris RL, Erritzoe D (2021). Self-blinding citizen science to explore psychedelic microdosing. eLife. link
- 3de Wit H, Molla HM, Bershad A, Bremmer M, Lee R (2022). Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study. Addiction Biology. link
- 4Cavanna F, Muller S, de la Fuente LA, Zamberlan F, Palmucci M, Janeckova L, Kuchar M, Pallavicini C, Tagliazucchi E (2022). Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. Translational Psychiatry. link
- 5Marschall J, Fejer G, Lempe P, Prochazkova L, Kuchar M, Hajkova K, van Elk M (2022). Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study. Journal of Psychopharmacology. link
- 6Polito V, Liknaitzky P (2024). Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research. Journal of Psychopharmacology. link
- 7Molla H, Lee R, Tare I, de Wit H (2024). Greater subjective effects of a low dose of LSD in participants with depressed mood. Neuropsychopharmacology. link
- 8Fadiman J (2011). The Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys. link
- 9Tagen M, Mantuani D, van Heerden L, Holstein A, Klumpers LE, Knowles R (2023). The risk of chronic psychedelic and MDMA microdosing for valvular heart disease. Journal of Psychopharmacology. link
- 10Rouaud A, Calder AE, Hasler G (2024). Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins. Journal of Psychopharmacology. link
- 11DEA (2024). Drug Scheduling: Schedule I Controlled Substances (Psilocybin, LSD). link
- 12Colorado General Assembly (2022). Proposition 122: Natural Medicine Health Act. link
დაკავშირებული სახელმძღვანელოში (3)
- — If you want the altered state without a substance, holotropic breathwork chases the same territory through breath.
- — Unlike microdosing, ketamine actually beats placebo for depression — a useful contrast in what 'psychedelic medicine' has proven.
- — The focus-and-creativity promise is the same one nootropics make — and microdosing fails it in blinded trials.
Microdosing Psilocybin and LSD
Home-cultivated psilocybin mushrooms cost under $50/year for personal-use quantities in Colorado where personal cultivation is decriminalized (Prop 122). Volumetric-LSD or sourced microdose courses run $100–$400 for a 6-week cycle. Compared to other psychiatric interventions, materially cheap; trivial-cost tier.
Sourcing, dose-titrating (capsuling dried powder or making a volumetric LSD tincture), maintaining a Fadiman-style 1-on/2-off schedule for 4–8 weeks, and tracking effects requires sustained low-grade attention. Not high effort per dose, but a real lifestyle shift across a course.
Open-label and observational samples consistently report mood improvement (Anderson 2019; Polito & Stevenson 2019; Hutten 2019). The largest self-blinded trial (Szigeti 2021, n=191) and four other double-blind designs found mood improved in both arms but microdose did not separate from placebo. A possible subgroup signal in mild-to-moderate depression (Molla 2024) survives; Polito & Stevenson also observed increased neuroticism. Net: a small but real on-dose mood effect, mostly placebo-mediated, with a fragile subgroup case.
Sparse and contested. Mechanism plausible (5-HT2A agonism, dose-proportional BDNF rise per Hutten 2020); multiple double-blind trials (Szigeti 2021, n=191; DeWit 2022, n=56; Cavanna 2022; Marschall 2022) consistently fail to separate microdose from placebo on mood, focus, and creativity. The 2024 rapid review (Polito & Liknaitzky) concluded the headline claims are best explained by placebo. No claim of 5 possible; sits between 1 and 2; lands at 2 because mechanism is real and a subgroup signal in depression survives.
On-dose days produce a small subjective vigor / bliss / mild stimulant-like signal in lab studies (DeWit 2022; Hutten 2020). Set against a ~6% rate of headache, fatigue, nausea, and sleep disruption in survey data (Hutten 2019) and ~15% jitteriness requiring titration in controlled LSD trials (DeWit 2022), the net felt-wellness effect is marginal and at the trivial end of the ladder.
Acute increase in self-reported vigor / arousal at 13–26 μg LSD in placebo-controlled lab work (DeWit 2022), with a corresponding small subjective energy lift on dose days in self-blinded community samples (Szigeti 2021). Tolerance builds across sessions; effect does not separate from placebo on durable energy measures.
Sustained-attention vigilance signal at low LSD doses in early lab work, but blinded trials show no separation from placebo on working memory or executive function and even slowing on creativity-related tasks (DeWit 2022; Cavanna 2022; Polito & Liknaitzky 2024). Reported focus benefits in open-label samples (Anderson 2019) are best explained by ritual and expectancy.